Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸»ÃÊ opioid ¼ö¿ëü¿¡ ÀÇÇÑ ÀúÀÛ±Ù ÅëÁõÀÇ Á¶Àý È¿°ú

Effect of Peripheral Opioid Receptor on Masticatory Muscle Pain Control

´ëÇѱ¸°­³»°úÇÐȸÁö 2013³â 38±Ç 2È£ p.161 ~ 174
°í¼®È£, °­¼ö°æ, ¾î±Ô½Ä, ±èÀºÃ¶, È«Á¤Ç¥, Àü¾çÇö,
¼Ò¼Ó »ó¼¼Á¤º¸
°í¼®È£ ( Ko Seok-Ho ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ¾È¸éÅëÁõ±¸°­³»°úÇб³½Ç
°­¼ö°æ ( Kang Soo-Kyung ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ¾È¸éÅëÁõ±¸°­³»°úÇб³½Ç
¾î±Ô½Ä ( Auh Q-Schick ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ¾È¸éÅëÁõ±¸°­³»°úÇб³½Ç
±èÀºÃ¶ ( Kim Eun-Cheol ) - °æÈñ´ëÇб³ Ä¡¾Æ¿Í Ä¡ÁÖÁ¶Á÷Àç»ý¿¬±¸¼¾ÅÍ(MRC)
È«Á¤Ç¥ ( Hong Jung-Pyo ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ¾È¸éÅëÁõ±¸°­³»°úÇб³½Ç
Àü¾çÇö ( Chun Yang-Hyun ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ¾È¸éÅëÁõ±¸°­³»°úÇб³½Ç

Abstract

ÀÌ ¿¬±¸´Â ÀúÀÛ±Ù ÅëÁõ ȯÀÚ¿¡°Ô MorphineÀ» ÁÖ»çÇÏ¿´À» ¶§ÀÇ Á¶Àý È¿°ú¸¦ È®ÀÎÇϱâ À§Çؼ­ ½ÃÇàµÇ¾úÀ¸¸ç, °æÈñ´ëÇб³ Ä¡°ú´ëÇк´¿ø ±¸°­³»°ú¿¡ ³»¿øÇÑ È¯ÀÚ Áß RDC/TMD·Î ±Ù¸·ÅëÁõÀ¸·Î Áø´ÜµÈ ȯÀÚµéÀÌ Áö¿øÇÏ¿´´Ù. ½ÇÇ豺Àº ÃÑ ³× ±ºÀ¸·Î ±¸¼ºµÇ¾úÀ¸¸ç saline Áֻ籺, lidocaine Áֻ籺, morphine 1.5 §· Áֻ籺, morphine 3.0 §· Áֻ籺¿¡ °¢°¢ 10¸í¾¿ ¹èÁ¤ÇÏ¿´´Ù. ÅëÁõºÎÀ§¿¡ ÁÖ»ç Àü, ÁÖ»ç ÈÄ 1½Ã°£, 24½Ã°£, 48½Ã°£¿¡ °¢°¢ ÁÖ°üÀûÀÎ ÅëÁõ Æò°¡ÀÎ ½Ã°¢À¯Ãßôµµ°Ë»ç, ¸Æ±æÅëÁõ¼³¹®Áö°Ë»ç ±×¸®°í ÅëÁõºÎÀ§Ç¥½Ã°Ë»ç¿Í °´°üÀûÀÎ ÅëÁõ Æò°¡ÀÎ ¾Ð·ÂÅëÁõ¿ªÄ¡°Ë»ç¿Í ¾Ð·ÂÅëÁõÇÑ°è°Ë»ç¸¦ ½Ç½ÃÇÏ¿´´Ù. °Ë»ç ÈÄ Æò°¡µÈ ÀڷḦ Åë°è ó¸®ÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú¸¦ ¾ò¾ú´Ù. 1. ÁÖ°üÀûÀÎ ÅëÁõÆò°¡¿¡¼­ morphine 3 §· ±ºÀº 48½Ã°£ ÈÄ Åë°èÇÐÀûÀ¸·Î À¯ÀǼº ÀÖ´Â È¿°ú°¡ ÀÖ¾ú´Ù.(VAS: p£¼0.01, MGQ: p£¼0.001, PD: p£¼0.05) 2. °´°üÀûÀÎ ÅëÁõÆò°¡¿¡¼­ morphine 1.5 §· ±ºÀº 1½Ã°£ ÈÄ Åë°èÇÐÀûÀ¸·Î À¯ÀǼº ÀÖ´Â È¿°ú°¡ ÀÖ¾ú´Ù.(PPT: p£¼0.01, PPTol: p£¼0.05) 3. ¸Æ±æÅëÁõ¼³¹®Áö¿¡¼­ lidocaine ±º, morphine 1.5 §· ±º ±×¸®°í morphine 3 §· ±ºÀº ¸ðµÎ óġ ÈÄ 1½Ã°£ºÎÅÍ È¿°ú°¡ ÀÖ¾úÀ¸³ª »ó´ëÀûÀ¸·Î morphine 3 §· ±º¿¡¼­ Åë°èÇÐÀûÀ¸·Î À¯ÀǼº ÀÖ°Ô ´õ Å« È¿°ú°¡ ÀÖ¾ú´Ù.(1h: p£¼0.01, 24h: p£¼0.01, 48h: p£¼0.001) ÀÌ»óÀÇ ¿¬±¸ °á°ú·Î ÀúÀÛ±Ù¿¡ ÅëÁõÀÌ Àִ ȯÀÚ¿¡°Ô morphine ÁÖ»ç ½Ã ÁÖ°üÀûÀÎ Æò°¡¿¡¼­ 48½Ã°£ ÈÄ ÅëÁõ Á¶Àý È¿°ú°¡ ÀÖ¾ú°í, morphine 3 §·ÀÌ ´õ È¿°ú°¡ ÀÖ¾úÀ¸¸ç, ÇâÈÄ ½Ã°£ ¿¬Àå¿¡ µû¸¥ Áö¼ÓÀûÀÎ Ãß°¡ ¿¬±¸°¡ ÇÊ¿ä ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.

This study was designed to evaluate the pain control effect by morphine injection to masticatory muscle pain patients. Patients with masticatory muscle pain visited the Department of Oral Medicine, Kyung Hee University Dental Hospital were recruited to this study and diagnosed by RDC/TMD. Experimental group were divided into four group; saline injection group (n=10), lidocaine injection group (n=10), morphine 1.5 §· injection group (n=10) and morphine 3 §· injection group (n=10). Evaluation list was the subjective pain evaluation(visual analogue scale, Mc Gill pain questionnaire, pain drawing) and the objective pain evaluation(pressure pain threshold, pressure pain tolerance) and evaluation time was injection before, after 1 hour, 24 hour, 48 hour and then it was analyzed statistically. The results were as follows : 1. The subjective pain evaluation were significantly different statistically in morphine 3 §· group after 48 hour. (VAS: p£¼0.01, §·Q: p£¼.001, PD: p£¼0.05) 2. The objective pain evaluation were significantly different statistically in morphine 1.5 §· group after 1 hour. (PPT: p£¼0.01, PPTol: p£¼0.05) 3. The morphine 3 §· group were more significantly different than lidocaine group and morphine 1.5 §· group statistically in the McGill pain questionnaire evaluation. (1h: p£¼0.01, 24h: p£¼0.01, 48h: p£¼0.001) Therefore, it was revealed that the morphine 3 §· injection was effective to pain control for masticatory muscle pain patients within 48 hours and more effect than lidocaine injection.

Å°¿öµå

ÀúÀÛ±Ù ÅëÁõ; ÃøµÎÇϾÇÀå¾Ö
Morphine sulfate; Masticatory Muscle Pain; Temporomandibular Disorders

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI